Article

CDER News 12/31/01 through 1/2/02

Original manufacturing supplements, original efficacy supplements, original and resubmitted NDAs, and new and generic drug approvals.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
Behind the Headlines, Episode 23: Patent Cliff Deals, Tariff Pressures, and the In Vivo Cell Therapy Bet
© 2025 MJH Life Sciences

All rights reserved.